Quebec announced Wednesday that it has facilitated access to hormone therapy in the general drug insurance plan to treat the symptoms of menopause.
Easy access to two bio-identical hormones, estradiol-17B in the form of a topical gel and micronized progesterone, covered by the Régie de l’assurance maladie du Québec, will be in effect as of Thursday.
The announcement by the Minister of Health and Social Services comes after problems with access to hormone therapy, while the reimbursement of these two drugs obeys rigid criteria that have now been abolished.
More than 260,000 women have signed the petition entitled “Loto-Méno: For access to bio-identical hormone therapy” after the issues raised by the opinion documentary “Loto-Méno” on Radio-Canada.
“This is an important step that we are taking for the benefit of the health and quality of life of Quebec women,” said Christian Dubé, Minister of Health and Social Services, in a press release.
“We have certainly heard and listened to the concerns raised by women regarding the management of menopausal symptoms, particularly with regard to improved access to hormone therapy. I salute their great mobilization,” added Mr. Dubé.
Reference-www.journaldequebec.com